2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

152 Vertebral compression fractures in newly diagnosed multiple myeloma: Risk factors and outcomes in the era of quadruplet induction

Arvind Suresh, MD, Pranav Ghaskadbi2, Jodi Lipof, MD3, Darren Pan, MD4, Anupama Deepa Kumar, MD5, Alfred Chung, MD6, Shagun Arora, MD7, Peter Sayre, MD8, Jeffrey Lee Wolf, MD9, Thomas Martin, MD10, Ajai Chari, MD11
1 University of California San Francisco, San Francisco, California, United States
2 University of California San Francisco, San Francisco, California, United States
3 University of California San Francisco, San Francisco, California, United States
4 University of California San Francisco, San Francisco, California, United States
5 University of California San Francisco, San Francisco, California, United States
6 University of California San Francisco, San Francisco, California, United States
7 University of California San Francisco, San Francisco, California, United States
8 University of California San Francisco, San Francisco, California, United States
9 University of California San Francisco, San Francisco, California, United States
10 University of California San Francisco, San Francisco, California, United States
11 University of California San Francisco, San Francisco, California, United States

Introduction
Multiple myeloma is characterized by osteolytic bone disease affecting up to 80% of newly diagnosed patients, with a 39.2% incidence of vertebral compression fractures (VCF). These skeletal-related events remain a major driver of morbidity and diminished quality of life. Despite the ability of anti-CD38 quadruplet induction regimens to achieve deeper, more durable responses and improve PFS/OS, their impact on skeletal outcomes and implications for duration of bone-directed therapy remain unclear. We examined the incidence and risk factors for VCF in patients with newly diagnosed multiple myeloma (NDMM) undergoing induction therapy at our center.

Methods
We conducted an IRB-approved single-center retrospective analysis of patients with NDMM diagnosed between 2015-2026 and identified those with at least one VCF. A HIPAA-compliant large language model (Versa) extracted baseline bone marrow involvement, treatments, VCF history, and associated dates from clinical documentation with manual chart validation in a 10% random subset. Response to induction was assessed per IMWG criteria and deep, rapid response was defined as a ≥50% decrease in M-protein or involved free light chain within 2 or 6 months of induction start. Univariate and multivariate logistic and Poisson regression identified factors associated with VCF risk and fracture event count. Outcomes following fracture were characterized by receipt of kyphoplasty/vertebroplasty or radiation therapy.

Results
Among 2472 consecutive patients with NDMM at our center, 752 (30.4%) developed at least one VCF (median 2, IQR 1-3). Among 1593 total VCF events, 533 (33.5%) occurred before/at diagnosis, 764 (48.0%) after treatment initiation, and 296 (18.6%) had unknown timing. Median age was 63 years (IQR 56-70). Patients were predominantly male (57.3%) and White (56.1%), with Latinx, Asian, and Black patients also represented. ISS stage I/II/III was 24.2%/39.0%/36.8%, respectively. CKD ≥stage 3 was present in 15.0%. Age and gender were well-matched between groups. Black patients were underrepresented among those with a VCF (5.7% vs 10.0%). 

Higher baseline bone marrow plasma cell percentage was independently associated with a greater rate of VCF events on multivariate Poisson regression across the full disease course (IRR 1.04 per 10% increase, 95% CI 1.02-1.06, p<0.001) and when restricted to treatment-emergent VCF within 6 months (IRR 1.09 per 10% increase, 95% CI 1.03-1.15, p=0.001). In a sensitivity analysis including ISS stage (available for 48.4%), ISS stage was the strongest predictor associated with treatment-emergent VCF within 6 months (IRR 1.72, 95% CI 1.29-2.31, p<0.001). Compared with patients without a VCF, those with a VCF also had higher-stage R-ISS disease (R-ISS 3: 21.0% vs 15.7%, p=0.05).

Of 391 patients with treatment-emergent VCF, 154 (39.4%) developed a VCF within 6 months of starting therapy. VCF incidence remained stable throughout the study period. Quadruplet induction, administered to 77/391 (19.7%) of these patients, was not associated with lower odds of a VCF in the first 6 months (OR 0.96, 95% CI 0.62-1.51, p=0.87), and also did not show any longer-term benefit at 24 months (OR 1.22, 95% CI 0.81-1.84, p=0.34). Achieving a deep, rapid response at 2 or 6 months, age, gender, and osteoporosis history were not significantly associated with post-induction VCF risk.

Bone-directed procedures were common: 258 patients (34.3%) underwent kyphoplasty/vertebroplasty and 265 (35.2%) received radiation therapy, with 99 (13.2%) undergoing both. Among patients with documented outcomes (n=124), symptomatic improvement was reported in 84.7%, with similar rates following radiation therapy and kyphoplasty/vertebroplasty.

Conclusion
In one of the largest cohorts evaluating VCF in NDMM patients receiving primarily weekly corticosteroids, baseline bone marrow plasma cell burden emerged as an independent predictor of VCF risk, which may inform earlier identification of patients warranting closer skeletal surveillance. Higher ISS stage was strongly associated with an increased risk of treatment-emergent VCF in the first 6 months after induction, while deep, rapid tumor debulking was not associated with increased post-induction VCF risk. Given the importance of skeletal health on quality of life and high incidence of VCF despite highly effective frontline strategies, a high index of suspicion and early referral for bone-directed procedures remain essential.

Arvind Suresh, MD: Doximity - Stock (publicly traded); Doximity - Honoraria; OpenEvidence - Honoraria